(701) Use of Tixagevimab and Cilgavimab (Evusheld) and Subsequent Outcomes of SARS-CoV-2 Infections in Lung Transplant Recipients

PURPOSE: The protection of solid organ transplant recipients from infection has been challenging throughout the Coronavirus disease (COVID-19) pandemic. In 2022, tixagevimab and cilgavimab (Evusheld) was introduced as a means of providing passive antibodies and augmenting the vaccine immune response...

Descripción completa

Detalles Bibliográficos
Autores principales: Grillini, A., Stracener, P., Scarola, D., Lyons, J., Dilling, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068082/
http://dx.doi.org/10.1016/j.healun.2023.02.715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068082/
http://dx.doi.org/10.1016/j.healun.2023.02.715

Ejemplares similares